Abstract: The solute carrier (SLC) transporter family constitutes a vital transmembrane protein system for maintaining cellular metabolic homeostasis. It is extensively involved in the transmembrane transport of diverse substances, including amino acids, glucose, lipids, metal ions and vitamins. In recent years, numerous studies have demonstrated that multiple SLC family members are aberrantly expressed in colorectal cancer (CRC). These aberrantly expressed SLC transporters drive the malignant progression of tumors through multiple mechanisms, such as mediating tumor metabolic reprogramming, promoting tumor invasion and metastasis, regulating the tumor immune microenvironment, and participating in therapeutic resistance. This article systematically reviews the molecular mechanisms underlying the involvement of SLC transporters in the initiation and progression of CRC, with a focus on summarizing their roles in metabolic regulation, immune evasion and therapeutic response of CRC. It further explores their clinical application value as diagnostic and prognostic biomarkers as well as potential therapeutic targets, aiming to provide a theoretical basis for the precision diagnosis and treatment of colorectal cancer.

Key words: Colorectal cancer, Solute carrier transporters, Metabolic reprogramming, Tumor immune microenvironment, Therapeutic resistance